

Supplementary Table S3.

Study Quality and Risk Assessment

Study authors and year of publication	Selection [†]			Comparability	Outcome		
	Representativeness of the exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study		Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts
Studies with GA Progression Data of Center-sparing and Center-involved GA							
Domalpally et al., 2013 AREDS	*	*	*	Did not control for other ocular diseases *	*	*	*
Holz et al., 2018 Chroma NCT02247479	Only included bilateral GA	*	*	**	*	*	*
Holz et al., 2018 Spectri NCT02247531	Only included bilateral GA	*	*	**	*	*	*
Keenan et al., 2018 AREDS2	*	*	*	**	*	*	*
Rosenfeld et al., 2019 SEATTLE NCT01802866	*	*	*	**	*	*	*
Studies with GA Progression Data of Fovea-sparing and Fovea-involved GA							
Allingham et al., 2016	*	*	*	* Did not define "foveal and extrafoveal lesions"	*	*	*
Monés et al., 2018 GAIN NCT01694095	*	*	*	* Did not define "foveal and extrafoveal lesions"	*	*	*
Schmitz-Valckenberg et al., 2016 GAP NCT00599846	*	*	*	**	*	*	*
Studies with GA Progression Data in ≥ 2 Topographic Regions							
Lindner et al., 2015 FAM NCT00393692	Only included eyes with GA that spares the fovea	*	*	**	Did not assess GA area in clearly predefined regions *	*	*
Mauschitz et al., 2012 GAP NCT00599846	*	*	*	**	*	*	*
Sayegh et al., 2017	*	*	*	**	*	*	*
Sunness et al., 1999	*	*	*	* Definition of the Central zone was much larger than other studies	*	*	*

GA, geographic atrophy;

[†]"Selection of the non exposed cohort" in the original NOS is not applicable to our study and thus not included in the quality assessment.